EMEA-002559-PIP06-22 - paediatric investigation plan

Nipocalimab
PIP Human

Key facts

Active substance
Nipocalimab
Therapeutic area
Neurology
Decision number
P/0509/2022
PIP number
EMEA-002559-PIP06-22
Pharmaceutical form(s)
Solution for injection
Condition(s) / indication(s)
Treatment of chronic inflammatory demyelinating polyradiculoneuropathy
Route(s) of administration
Subcutaneous use
Contact for public enquiries

Janssen Cilag International NV

Tel. +3214602111
E-mail: contact@Janssen-emea.com

Decision type
W: decision granting a waiver in all age groups for all conditions or indications
Decision date
Compliance check done
No

Decision

Share this page